Supply of Material a) All Advertisement Copy (subject to any other terms in the Booking Confirmation) is to be delivered carriage paid and shall be supplied to the Contractor at the place(s) and within the time specified in the Booking Confirmation. All Advertisement Copy shall be produced and supplied to the Contractor in accordance with the Production Specifications.
Supply of Material. The Bank may supply the Merchant with promotional material for the System, and the Merchant may at its discretion display at the Premises any of the material supplied by the Bank.
Supply of Material. 10.01 Licensor shall provide, or shall cause its Affiliates to provide (i) Licensor Material in possession of Licensor as of the Effective Date at the request of Licensee, to the extent that it is possible for Licensor to so provide and (ii) cGMP Compound and Non-cGMP Compound from among existing stocks as of the Effective Date. The Parties acknowledge that Licensor has in its possession approximately 7.9 kilograms of Compound manufactured in accordance with cGMP (“cGMP Compound”) and approximately 35 kilograms of Compound manufactured not in accordance with cGMP (‘‘Non-cGMP Compound”). Licensor agrees to sell to Licensee pursuant to a one-time purchase order delivered by Licensee to Licensor up to such amount of cGMP Compound as it may now have in its possession and to transfer to Licensee at no cost up to five (5) kilograms of Non-cGMP Product. Promptly following execution and delivery of this Agreement, Licensor shall take stock of its supply of cGMP Compound and inform Licensee of the quantity on hand.
Supply of Material. OPKO will, * transfer to TESARO in accordance with the Technology Transfer Plan all quantities of API and Licensed Product in OPKO’s possession or control. To the extent such API or Licensed Product is identified as GMP-grade materials in the Technology Transfer Plan, OPKO represents that (i) since OPKO’s acquisition of such materials, OPKO has handled and stored such materials in accordance with current Good Manufacturing Practices as defined in the U.S. (“GMP”), and (ii) nothing has come to OPKO’s attention which leads it to believe that any such material has not been manufactured and stored in accordance with GMP, that it would not conform in all material respects to the applicable specifications or would not be fit for use in clinical trials pursuant to FDA guidelines and requirements. OPKO will provide copies of batch records and certificates of compliance in its possession with respect to such material. In addition, OPKO will, at the request of TESARO, require Merck & Co., Inc. to deliver the Hold Back API, as defined in the Asset Purchase Agreement, to TESARO or its designee, and to supply addition quantities of API to the extent consistent with Merck & Co., Inc.’s obligation under Section 7.11(b) of the Asset Purchase Agreement on terms to be approved by TESARO.
Supply of Material. Biogen shall provide the Institution, at no charge, with such quantities of the Product or placebo and other material, equipment or goods as may be required for a Trial and as Biogen may elect to make available (the “Material”). The Institution shall have no liability for any failure to fulfill its obligations as a result of the unavailability of the Material. The Institution shall use the Material only pursuant to and in accordance with the Protocol. The Institution shall not use, and shall not permit an Investigator to use, the Material for any other purpose without the prior written consent of Biogen. The supply terms of the Material, including the relevant financial terms, are included in Schedule A hereto. The Institution shall treat, handle, use and maintain, as applicable, the Material with the degree of care used for its own property and in accordance with the instructions of Biogen or its agents at any time. At the conclusion or termination of the Trial, the Institution shall account for all quantities used of the Material and, unless otherwise agreed in writing by the parties, shall return or otherwise dispose of all remaining Material in accordance with the instructions of Biogen or its agents.
Supply of Material. (a) SiTech hereby agrees to manufacture for, and deliver exclusively to Mentor, and Mentor agrees to purchase from SiTech, such quantities of the Materials to meet Mentor requirements based upon such written purchase orders and forecasts provided Pursuant to Section 2.3 hereof. In the event that Mentor's requirements differ significantly (by more than 10%) from the forecasts, Mentor will promptly notify SiTech of the fact and of the amount of such variance, and SiTech shall use its best efforts to accommodate any variance upon receiving notice thereof from Mentor. The parties hereto acknowledge and agree that SiTech may manufacture or sell other products to any third party upon the prior written consent of Mentor, which consent may be withheld by Mentor at Mentor's sole and absolute discretion.
Supply of Material. Promptly after the Effective Date, NAIST shall supply RECIPIENT, free of charge, with the material called [ ] (hereinafter “Material”) in the quantity of [ ] milligrams, sending by courier to RECIPIENT’s address stated hereinabove.
Supply of Material. CureVac will use Commercially Reasonable Efforts to supply to CRISPR, its Affiliates and Sublicensees the Materials set forth in Attachment C hereof. CRISPR will use such Materials only in accordance with the Work Plan as set forth in Attachment D and otherwise in accordance with the terms and conditions of this Agreement and will not reverse engineer or chemically analyze the Material except as expressly provided for in the Work Plan.
Supply of Material. Novartis will make available for pick up by AVEO the material and associated documentation identified on Exhibit A (the “Material”) within [**] after the later of (i) the Agreement Effective Date, or (ii) the date that AVEO provides all information and data reasonably necessary to transfer the Material in compliance with applicable law and/or cGMP (to the extent applicable); provided, however, notwithstanding the foregoing, and to the extent required by cGMP and the Parties’ respective Quality Assurance functions, cGMP Material will be transferred only following the execution of a commercially reasonable Quality Agreement between the Parties (as described below). The Material will be transferred Ex Works (Incoterms 2010) and except as provided on Exhibit A, is transferred “as is” and without representation or warranty of any kind and Novartis disclaims any implied warranties of merchantability or fitness for a particular purpose with respect to the Material; provided, however, that Novartis represents that, with respect to materials manufactured in accordance with cGMP, Novartis handled, stored and transported, and, until it is picked up by AVEO, will continue to handle, store and transport, the Material in accordance with cGMP for biological products. The Parties will enter into a commercially reasonable Quality Agreement with respect to the cGMP Material following the execution of this Agreement. Novartis will share with AVEO all material safety data sheets and customs value information that is reasonably available to Novartis, including without limitation Licensed Antibodies-specific information, as is reasonably necessary to permit AVEO to pick up the Material. AVEO will be solely responsible for any re-testing associated with the Material prior to use. Upon pick up by AVEO, Novartis will have no further obligation to replace lost or damaged material or to provide additional services with respect to such Material.
Supply of Material. (a) As soon as reasonably practical after the Effective Date but in any event within ninety (90) days after the Effective Date, Biogen shall deliver to TMC Biogen's existing inventory of Peptide as described in APPENDIX F (the "Biogen Inventory"). In addition, Biogen shall, at TMC's request, provided such request is made prior to September 18, 1997 (the "Completion Option Period"), initiate completion of processing by UCB Bioproducts S.A. (collectively "UCB") of approximately 30kg of Peptide intermediates (expressed in equivalent bulk drug substance quantities) stored at UCB as of the Effective Date under the terms of a Supply Agreement between Biogen and UCB, dated as of March 21,1997 (the "Supply Agreement") (a copy of which has been provided to TMC, and shall deliver to TMC the resulting material (the "UCB Material"). TMC understands and agrees that "processing", as the term is used in this Section, of the 30kg of Peptide intermediates by UCB shall mean completion of the manufacturing of such portion of the 30kg of Peptide intermediates as UCB, in consultation with Biogen and TMC, determines is viable for further production (the "Unfinished Peptide") using
